EMPIRIKAL – A Double Blind Randomized Controlled Investigation into the efficacy of Mirococept (APT070) for preventing ischaemia-reperfusion injury in the kidney allograft (EMPIRIKAL)
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs Mirococept (Primary)
- Indications Reperfusion injury
- Focus Therapeutic Use
- Acronyms EMPIRIKAL
- 06 Jun 2017 Trial design published in the Trials.
- 11 Mar 2016 Accrual to Date is 3% as per United Kingdom Clinical Research Network record.
- 11 Mar 2016 Planned End Date changed from 30 Apr 2016 to 31 Mar 2017 as per United Kingdom Clinical Research Network record.